A biomaterial collection device can include a wire that includes a functional member including a proximal end, a distal end, a first flat surface and a second flat surface opposing the first surface. The functional member can be configured to fit within a body lumen. The functional member can include binding elements configured to bind circulating biomolecules and cells. The functional member can include curved portions that form revolutions around the longitudinal axis of the device.

An immunoassay cartridge is disclosed that can enhance the reliability of an antigen-antibody reaction while increasing a speed of an antigen-antibody reaction. An immunoassay cartridge includes a reaction chamber and a fluorescence sensor assembly. A plurality of antibodies or antigens is attached to an inner surface including a bottom surface of the reaction chamber closest to the sensor. The fluorescence sensor assembly is disposed on a bottom surface of the reaction chamber. Since the bottom surface of the reaction chamber and the upper surface of the fluorescence sensor assembly are arranged to coincide with each other, even if fluid is repeatedly moved in a first direction after the fluid moves in a second direction in the reaction chamber and then moved in the first direction, there is no obstacle in the movement of the fluid. Thus, it is possible to increase the probability of antigen-antibody reaction in the reaction chamber.

Some embodiments of the disclosure provide a time-resolved fluorescent immunochromato-graphic test strip for detecting vancomycin as well as a preparation method and application thereof. In some embodiments, the test strip includes a bottom plate and a sample absorption pad. A fluorescent microsphere pad, a nitrocellulose membrane coated with a vancomycin-carrier protein conjugate, and an absorbent pad are sequentially overlapped and pasted on the bottom plate. The fluorescent microsphere pad is sprayed with a fluorescent microsphere-labeled vancomycin monoclonal antibody, and the vancomycin monoclonal antibody is prepared by using a vancomycin-bovine serum albumin conjugate as an immunogen.

A microfluidic device is contemplated comprising an open-top cavity with structural anchors on the vertical wall surfaces that serve to prevent gel shrinkage-induced delamination, a porous membrane (optionally stretchable) positioned in the middle over a microfluidic channel(s). The device is particularly suited to the growth of cells mimicking dermal layers.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Disclosed are systems, devices and methods for a quantitative aptamer-based viral assay. In some aspects, an aptamer-based viral assay device includes a substrate and a biochemical complex conjugated to the substrate, which comprises an aptamer that is initially bound to an enzyme-tagged complementary strand of nucleotides, the aptamer corresponding to an antigen of a virus (e.g., SARS-CoV-2) that has a higher binding affinity to the aptamer than the complementary strand of nucleotides, wherein, when the device is exposed to a solution containing the virus, the enzyme-tagged strand is released from the aptamer as the aptamer binds the antigen of the virus, such that the released enzyme is capable of converting a substance to an analyte that is measurable by a remote analyte meter to correlate with a parameter of the virus in the solution.

The invention relates generally to serology assays and, more particularly, to high-throughput serology assays. One aspect of the invention provides a method of detecting a viral antibody in a biological sample of an individual, the method comprising: applying an antigen-containing fluid to an assay surface, the antigen-containing fluid containing an antigen for the vims to be detected and the assay surface containing a biological sample from the individual; removing the antigen-containing fluid from the assay surface; and determining whether the assay surface contains bound antigen.

Methods for enhancing the binding rate between at least two particulate binding partners are disclosed. Methods include flowing a first binding partner and a second binding partner, e.g., in a viscoelastic fluid, under conditions to chemically bind the first binding partner and the second binding partner to create a third binding partner. The flow conditions induce a particle size dependent, migration, e.g., radial, velocity differential between the first binding partner and the second binding partner and between the first binding partner and third binding partner, e.g., to increasing a collision frequency of the nanoparticles and the larger particles. Devices for enhancing the binding rate between at least two particulate binding partners are also disclosed.

Compositions, systems, and methods are disclosed for preparing and utilizing arrays, such as single-analyte arrays containing a plurality of fiducial elements with random spatial distributions. Arrays may be prepared with pluralities of fiducial elements comprising optically active or passive moieties. Arrays containing random spatial distributions of fiducial elements may be utilized for various array-based processes that require spatial information.

A method can include measuring increments in a response signal in multiple sample injection sessions in a sensing channel until the response signal reaches a threshold response capacity. Measuring the increments can include: (a) starting a respective sample injection session of the multiple sample injection sessions by injecting a sample with an analyte to the sensing channel; (b) controlling the valve port to terminate the respective sample injection session; (c) measuring the response signal based on a reaction between the sample and the ligand; and/or (d) upon determining that the response signal is not greater than the threshold response capacity, determining a respective response increment of the increments for the respective sample injection session, and starting a subsequent session of the multiple sample injection sessions for determining a subsequent increment of the increments. The method further can include determining an analyte concentration of the sample based at least in part on the increments. Other embodiments are disclosed.